Analytical Data
-
Gene name
TP53BP1
- Application
-
Alternative Names
TP53BP1；TP53-binding Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q12888
-
Expression Region
全长
-
AA Sequence
full
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TP53BP1 (Tumor Protein p53 Binding Protein 1) is a critical protein involved in the cellular response to DNA damage and the maintenance of genomic stability, making it a significant focus in cancer research. This protein acts as a mediator in the pathway of DNA double-strand break repair, interacting with various components of the DNA damage response (DDR) machinery. Mutations or dysregulation of TP53BP1 have been associated with increased susceptibility to cancer and poor prognosis in affected individuals, particularly in cancers linked to genomic instability. Researchers have increasingly turned their attention to recombinant forms of TP53BP1 to better understand its structural and functional properties. By studying these recombinant proteins, scientists aim to elucidate the mechanisms underlying TP53BP1's role in DDR and its interactions with other proteins, such as p53, BRCA1, and RAD51. Furthermore, the development of recombinant TP53BP1 can facilitate investigations into therapeutic strategies that target DDR pathways, offering potential advancements in cancer treatment and personalized medicine. The intricate balance TP53BP1 maintains in regulating apoptosis and cell cycle checkpoints underscores its relevance in not only tumorigenesis but also in the broader context of cellular health. As research progresses, understanding the detailed functions of TP53BP1 through its recombinant forms may lead to innovative approaches in combating various malignancies and enhancing the efficacy of existing therapies. This ongoing study of TP53BP1 represents a promising frontier in both basic and translational cancer research, aiming to unveil new insights that could pave the way for novel diagnostic and therapeutic options.
